In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
The price of Transmedics Group Inc (NASDAQ: TMDX) closed at $116.05 in the last session, down -2.31% from day before closing price of $118.8. In other words, the price has decreased by -$2.31 from its previous closing price. On the day, 0.87 million shares were traded. TMDX stock price reached its highest trading level at $120.325 during the session, while it also had its lowest trading level at $114.33.
Ratios:
We take a closer look at TMDX’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 9.88 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 228.02. For the most recent quarter (mrq), Quick Ratio is recorded 9.17 and its Current Ratio is at 9.86. In the meantime, Its Debt-to-Equity ratio is 1.63 whereas as Long-Term Debt/Eq ratio is at 1.62.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, JP Morgan on December 17, 2024, Downgraded its rating to Neutral and sets its target price to $75 from $116 previously.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Aug 04 ’25 when Basile Edward M sold 4,143 shares for $125.51 per share. The transaction valued at 519,988 led to the insider holds 2,866 shares of the business.
EDWARD BASILE bought 4,143 shares of TMDX for $519,988 on Aug 04 ’25. On Jun 09 ’25, another insider, Ranganath Anil P., who serves as the insider of the company, sold 686 shares for $139.80 each. As a result, the insider received 95,903 and left with 13,955 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TMDX now has a Market Capitalization of 4049936128 and an Enterprise Value of 4074432768. As of this moment, Transmedics’s Price-to-Earnings (P/E) ratio for their current fiscal year is 60.01, and their Forward P/E ratio for the next fiscal year is 42.49. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.14. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.45 while its Price-to-Book (P/B) ratio in mrq is 12.42. Its current Enterprise Value per Revenue stands at 7.669 whereas that against EBITDA is 40.622.
Stock Price History:
The Beta on a monthly basis for TMDX is 2.18, which has changed by -0.287556 over the last 52 weeks, in comparison to a change of 0.18634176 over the same period for the S&P500. Over the past 52 weeks, TMDX has reached a high of $177.37, while it has fallen to a 52-week low of $55.00. The 50-Day Moving Average of the stock is -6.55%, while the 200-Day Moving Average is calculated to be 27.07%.
Shares Statistics:
According to the various share statistics, TMDX traded on average about 1.11M shares per day over the past 3-months and 1551350 shares per day over the past 10 days. A total of 34.04M shares are outstanding, with a floating share count of 32.86M. Insiders hold about 3.60% of the company’s shares, while institutions hold 117.06% stake in the company. Shares short for TMDX as of 1752537600 were 7995364 with a Short Ratio of 7.21, compared to 1749772800 on 7860937. Therefore, it implies a Short% of Shares Outstanding of 7995364 and a Short% of Float of 40.400000000000006.
Earnings Estimates
The current rating of Transmedics Group Inc (TMDX) reflects the combined expertise of 6.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is $0.4, with high estimates of $0.47 and low estimates of $0.29.
Analysts are recommending an EPS of between $2.58 and $1.73 for the fiscal current year, implying an average EPS of $2.25. EPS for the following year is $2.7, with 6.0 analysts recommending between $3.25 and $2.2.
Revenue Estimates
According to 8 analysts, the current quarter’s revenue is expected to be $144.99M. It ranges from a high estimate of $148.6M to a low estimate of $140.5M. As of the current estimate, Transmedics Group Inc’s year-ago sales were $108.76MFor the next quarter, 8 analysts are estimating revenue of $155.14M. There is a high estimate of $159.8M for the next quarter, whereas the lowest estimate is $148.61M.
A total of 9 analysts have provided revenue estimates for TMDX’s current fiscal year. The highest revenue estimate was $605M, while the lowest revenue estimate was $582.2M, resulting in an average revenue estimate of $599.4M. In the same quarter a year ago, actual revenue was $441.54MBased on 9 analysts’ estimates, the company’s revenue will be $719.59M in the next fiscal year. The high estimate is $752.9M and the low estimate is $687.4M.
